The potential of γδ CAR and TRuC T cells: An unearthed treasure.
Eur J Immunol
; : e2451074, 2024 Aug 27.
Article
em En
| MEDLINE
| ID: mdl-39192467
ABSTRACT
Recent years have witnessed the success of αß T cells engineered to express chimeric antigen receptors (CARs) in treating haematological cancers. CARs combine the tumour antigen binding capability of antibodies with the signalling functions of the T-cell receptor (TCR) ζ chain and co-stimulatory receptors. Despite the success, αß CAR T cells face limitations. Possible solutions would be the use of γδ T cells and new chimeric receptors, such as TCR fusion constructs (TRuCs). Notably, γδ CAR T cells are gaining traction in pre-clinical and clinical studies, demonstrating a promising safety profile in several pilot studies. This review delves into the current understanding of γδ CAR and TCR fusion construct T cells, exploring the opportunities and challenges they present for cancer treatment.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
Eur J Immunol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Alemanha